IL246643B - Compositions and kits for treating human immunodeficiency virus/accquired immunodeficiency syndrome - Google Patents

Compositions and kits for treating human immunodeficiency virus/accquired immunodeficiency syndrome

Info

Publication number
IL246643B
IL246643B IL246643A IL24664316A IL246643B IL 246643 B IL246643 B IL 246643B IL 246643 A IL246643 A IL 246643A IL 24664316 A IL24664316 A IL 24664316A IL 246643 B IL246643 B IL 246643B
Authority
IL
Israel
Prior art keywords
kits
preparations
treatment
immunodeficiency
syndrome
Prior art date
Application number
IL246643A
Other languages
English (en)
Hebrew (he)
Other versions
IL246643A0 (en
Original Assignee
Immunovative Therapies Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunovative Therapies Ltd filed Critical Immunovative Therapies Ltd
Publication of IL246643A0 publication Critical patent/IL246643A0/en
Publication of IL246643B publication Critical patent/IL246643B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL246643A 2014-01-08 2016-07-06 Compositions and kits for treating human immunodeficiency virus/accquired immunodeficiency syndrome IL246643B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461924936P 2014-01-08 2014-01-08
PCT/US2015/010658 WO2015105999A1 (en) 2014-01-08 2015-01-08 Treatment of human immunodeficiency virus/acquired immunodeficiency syndrome

Publications (2)

Publication Number Publication Date
IL246643A0 IL246643A0 (en) 2016-08-31
IL246643B true IL246643B (en) 2020-02-27

Family

ID=53494410

Family Applications (1)

Application Number Title Priority Date Filing Date
IL246643A IL246643B (en) 2014-01-08 2016-07-06 Compositions and kits for treating human immunodeficiency virus/accquired immunodeficiency syndrome

Country Status (12)

Country Link
US (3) US10272143B2 (enExample)
EP (1) EP3091990B1 (enExample)
JP (1) JP6557240B2 (enExample)
KR (1) KR102503400B1 (enExample)
CN (1) CN105899219B (enExample)
AU (1) AU2015204770B2 (enExample)
BR (1) BR112016015736B1 (enExample)
CA (1) CA2936086C (enExample)
IL (1) IL246643B (enExample)
PH (1) PH12016501359A1 (enExample)
SG (2) SG10201908048QA (enExample)
WO (1) WO2015105999A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150305983A1 (en) * 2009-11-20 2015-10-29 The University Of Versailles Saint-Quentin-En- Yvelines Quadruple therapy useful for treating persons afflicted with the human immunodeficiency virus (hiv)
US20190069528A1 (en) * 2016-03-21 2019-03-07 The George Washington University Engineered human hookworms as a novel biodelivery system for vaccines and biologicals
CN111886249A (zh) * 2017-09-18 2020-11-03 西托戴恩股份有限公司 用于鉴定和治疗适合长期抗-ccr5剂治疗的hiv-1感染患者亚群的筛选方法
USD1001795S1 (en) 2019-10-01 2023-10-17 Microsoft Corporation Computing device

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020022034A1 (en) * 1997-09-15 2002-02-21 Julianna Lisziewicz Therapeutic DNA vaccination
WO2000066141A2 (en) 1999-05-04 2000-11-09 Schering Corporation Pegylated interferon alfa-ccr5 antagonist combination hiv therapy
US6579521B2 (en) 2000-10-20 2003-06-17 Chiron Corporation Methods of therapy for HIV infection
US7402431B2 (en) 2004-03-01 2008-07-22 Immunovative Therapies, Ltd. T-cell therapy formulation
US20110142887A1 (en) * 2009-12-15 2011-06-16 Immunovative Therapies Ltd. Methods and compositions for liquidation of tumors
US7435592B2 (en) 2003-05-13 2008-10-14 Immunovative Therapies, Ltd. Compositions for allogeneic cell therapy
KR20070019635A (ko) * 2003-08-28 2007-02-15 더 임뮨 리스판스 코포레이션 면역원성 hiv 조성물 및 이와 관련된 방법
OA13246A (en) 2003-08-28 2007-01-31 Immune Response Corp Inc Immunogenic HIV Compositions and related methods.
JP2007525225A (ja) * 2004-02-26 2007-09-06 イミュノバティブ セラピーズ, リミテッド 細胞治療のためのt細胞を調製するための方法
EP1749090B1 (en) 2004-03-01 2017-05-17 Immunovative Therapies, Ltd. Cell therapy formulation method and composition
US8043619B2 (en) * 2004-10-08 2011-10-25 Yaron Ilan Methods and uses of leptin in immune modulation
US9695397B2 (en) 2008-10-01 2017-07-04 Immunovative Therapies Ltd. Th1 vaccination priming for active immunotherapy
US20120128656A1 (en) 2008-05-02 2012-05-24 Immunovative Therapies, Ltd. Vaccine compositions and methods
WO2010051521A1 (en) 2008-10-31 2010-05-06 Lentigen Corporation Cell therapy product for the treatment of hiv infection
WO2011077100A1 (en) * 2009-12-24 2011-06-30 Cipla Limited Antiretroviral composition
MX2012011189A (es) 2010-03-26 2013-02-07 Glaxosmithkline Biolog Sa Vacuna contra el virus e inmunodeficiencia humana.
AU2011240752B2 (en) * 2010-04-13 2016-07-28 Immunovative Therapies, Ltd. Methods and compositions for inhibition of Treg cells
WO2011130247A2 (en) 2010-04-14 2011-10-20 The Penn State Research Foundation Strategies for the transgenic manipulation of filamentous fungi

Also Published As

Publication number Publication date
US10729754B2 (en) 2020-08-04
EP3091990A4 (en) 2017-10-04
IL246643A0 (en) 2016-08-31
AU2015204770A1 (en) 2016-08-18
JP2017502058A (ja) 2017-01-19
WO2015105999A1 (en) 2015-07-16
EP3091990A1 (en) 2016-11-16
BR112016015736A2 (enExample) 2017-08-08
US20180200348A1 (en) 2018-07-19
PH12016501359A1 (en) 2016-08-22
EP3091990B1 (en) 2021-05-12
CA2936086A1 (en) 2015-07-16
CN105899219A (zh) 2016-08-24
AU2015204770B2 (en) 2020-07-02
SG10201908048QA (en) 2019-10-30
US20150190488A1 (en) 2015-07-09
US20200368334A1 (en) 2020-11-26
US10272143B2 (en) 2019-04-30
KR20160124096A (ko) 2016-10-26
CA2936086C (en) 2024-02-27
CN105899219B (zh) 2021-08-13
SG11201605440TA (en) 2016-08-30
BR112016015736B1 (pt) 2022-01-04
KR102503400B1 (ko) 2023-02-23
JP6557240B2 (ja) 2019-08-07

Similar Documents

Publication Publication Date Title
IL280459A (en) Phosphoramidates for the treatment of hepatitis b virus
IL261082A (en) Compositions and methods for modifying genomes
IL258955A (en) Compositions and methods for treatment of cancer
DK3805376T3 (da) Modificeret virus
EP3960735C0 (en) QUINAZOLINE DERIVATIVES USED TO TREAT HIV
HRP20181130T1 (hr) Postupci za liječenje infekcija virusom filoviridae
HRP20190352T1 (hr) Novi 6-kondenzirani heteroarildihidropirimidini za liječenje i profilaksu infekcije virusom hepatitisa b
DK3349758T3 (da) Fremgangsmåder til behandling af arenaviridae-virusinfektioner
DK3504187T3 (da) Anvendelse af pridopidin til behandling af funktionel tilbagegang
BR112016030968A2 (pt) análogos de pridopidina, preparação e uso destes
IL258459A (en) Therapeutic compositions for treatment of human immunodeficiency virus
IL252418B (en) Envenomation therapies and related pharmaceutical compositions, systems and kits
DK3191489T3 (da) Pyrrolopyrimidiner til anvendelse ved influenzavirusinfektion
PL3198009T3 (pl) Onkolityczne wirusy nowotworowe i sposoby zastosowania
LT3200815T (lt) Būdai ir kompozicijos, skirti vėžio gydymui
HRP20180639T1 (hr) Derivati izoindolina, namijenjeni upotrebi u liječenju virusne infekcije
HUE050944T2 (hu) Kezelési eljárás tradipitant alkalmazásával
IL249660A0 (en) Methods for treating hepatitis b virus and hepatitis d virus infections
PL3236960T3 (pl) Fluralaner do zastosowania w leczeniu demodekozy
LT3169307T (lt) Vandeninė kompozicija, apimanti paracetamolį ir ibuprofeną
IL262929A (en) Composition, and application and pharmaceutical preparation thereof
LT3137078T (lt) Virusinio hepatito delta infekcijos gydymas
IL248779A0 (en) Pharmaceutical compositions for treating infectious diseases
EP3493821A4 (en) METHOD OF TREATING THE RESPIRATORY TRACT
IL251345A0 (en) Compositions for use in the treatment of peri-implantitis

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed